Advertisement

Topics

Latest "Gritstone Oncology" News Stories - Page: 3

03:20 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Gritstone Oncology" found in our extensive news archives from over 250 global news sources.

More Information about Gritstone Oncology on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Gritstone Oncology for you to read. Along with our medical data and news we also list Gritstone Oncology Clinical Trials, which are updated daily. BioPortfolio also has a large database of Gritstone Oncology Companies for you to search.

Showing "Gritstone Oncology" News Articles 51–75 of 4,600+

Relevant

Just another week ahead in the biotech equity capital markets. Five #biotech #IPOs expected to price: Entasis, Arvinas, Sutro, Urovant, and Gritstone. $ETTX, $ARVN, $STRO, $UROV, $GRTS.

Just another week ahead in the biotech equity capital markets. Five #biotech #IPOs expected to price: Entasis, Arvinas, Sutro, Urovant, and Gritstone. $ETTX, $ARVN, $STRO


Gritstone Oncology Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17042018] Prices from USD $250

SummaryGritstone Oncology Inc Gritstone is a cancer immunotherapy company which focuses on the development of personalized cancer therapeutics. The company primarily concentrates on identifying and deploying the therapeutic neoantigens from individual patients' tumors for the development of novel treatments for lung cancer. Gritstone works in collaboration with other organizations such as Immune D...

Gritstone Oncology Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryGritstone Oncology Inc Gritstone is a cancer immunotherapy company that focuses on the development of personalized cancer therapeutics. The company primarily concentrates on identifying and deploying the therapeutic neoantigens from individual patients' tumors for the development of novel treatments for cancer. Gritstone also develops and commercializes immunotherapy drugs which includes ch...


GSK indicates oncology intent with €3.7bn Merck deal

GSK moves to rebuild its oncology pipeline by partnering with Merck KGaA on an immuno-oncology drug candidate.

US FDA approves Catalent’s collaborative oncology treatment

Oncology drug Copiktra was developed during a multi-year collaboration between Catalent Pharma and Verastem Oncology.

ESMO Immuno-Oncology Congress: where the community of stakeholders meets

(European Society for Medical Oncology) The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the ESMO Immuno-Oncology 2018 Congress, a dedicated platform in Europe to keep professionals up to date with the most recent and significant developments in this rapidly evolving field.

Avacta Group event to focus on immuno-oncology advances and role of its technology in the emerging field of science

Dr Josep Tabernero, President of the European Society for Medical Oncology and Head of the Val d'Hebron Institute of Oncology, Barcelona, will give the plenary presentation

Eli Lilly Deepens Its Oncology Offerings with an $8 Billion Acquisition of Loxo Oncology

Eli Lilly and Company announced it was buying Loxo Oncology for $235 per share in cash, which comes to about $8 billion. The acquisition adds a lot of weight to Lilly’s oncology efforts.

Oncology Venture - Multiple programme updates

Edison Investment Research - Pharmaceuticals & healthcare - Oncology Venture: Oncology Venture (OV) continues to provide regular response data from its ongoing LiPlaCis Phase II trial in patients w...

The Integrative Oncology Scholars Program: Indoctrinating the next generation of “integrative oncology” believers

"Integrative oncology" involves "integrating" pseudoscience, mysticism, and quackery with science-based oncology and co-opting science-based lifestyle modalities as "alternative" in order to provide cover for the quackery. Unfortunately, my alma mater, funded by the National Cancer Institute, is running a course to indoctrinate 100 health care professionals in the ways of "integrative oncology." T...

Men and women are different: Why medical oncology needs to restate the obvious

(European Society for Medical Oncology) Gender-based approaches to studying and treating disease have remained largely unexplored in medical oncology, despite the field's growing interest in precision medicine and accumulating evidence that sex is a major factor in disease risk and response to treatment. At the ESMO workshop, 'Gender medicine meets oncology,' to be held in Lausanne, Switzerland, o...

ESMO Immuno-Oncology Congress showcases new technologies set to improve cancer treatment

(European Society for Medical Oncology) Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

Hard Lessons From Year 1 of Oncology Fellowship

Loss of autonomy. Practicing in areas of medicine without good evidence. Providing end-of-life care. Oncology fellowship comes with its own unique set of tough lessons. Medscape Oncology

ESMO 2018 awardees announced

(European Society for Medical Oncology) The European Society for Medical Oncology (ESMO), the leading organisation for medical oncology, has revealed the four distinguished oncology professionals who will receive its annual awards during the ESMO 2018 Congress, 19-23 October, Munich, Germany.

Lilly to Pay $8 Billion to Acquire Loxo Oncology

Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with...

FDA Approves an Oncology Drug That Targets a Key Genetic Driver of Cancer

NewsLoxo Oncology's new drug Vitrakvi targets specific receptor kinase that promotes tumors.

Five practice changing shifts in oncology

Dr Howard 'Jack' West speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about five important practise changing shifts currently happening in oncology. These topics include molecular oncology, information dissemination, 'e-patients', the 'spectrum'...

Champions Oncology, Inc.: Champions Oncology Reports Quarterly Revenue of $6.7 Million

Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, NJ / ACCESSWIRE / December 17, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end r...

Ipsen strengthens oncology R&D team with two experts

French pharma company Ipsen has hired two R&D leaders to boost the company’s oncology arm. The new recruits – Dr Yan Moore and Dr Alexander (Sandy) McEwan – will bring their expertise to the company, which specialises in oncology, neuroscience...

AZ appoints controversial doctor to lead new oncology unit

AstraZeneca has a new and controversial oncology head after the departure of two key leaders led to a management reshuffle. CEO Pascal Soriot has picked cancer doctor José Baselga as the company’s new oncology R&D head – and while no-one would...

AstraZeneca, AVEO Oncology form lung cancer collaboration

AVEO Oncology has announced the start of an immuno-oncology focused clinical collaboration with drug giant AstraZeneca (AZ).

A whole issue of JACM devoted to “integrative oncology” propaganda? Oh, goody.

Last week, The Journal of Alternative and Complementary Medicine published a Special Focus Issue on "integrative oncology." In reality, it's propaganda that promotes pseudoscience and the "integration" of quackery into oncology.

With numerous product handoffs, immuno-oncology trials require a tight-knit supply chain

Immuno-oncology clinical trials are fundamentally different from traditional oncology studies as it pertains to logistics, and require close coordination across several stakeholders, says CRO.

TAT International Congress 2019: The home of phase I oncology

(European Society for Medical Oncology) The European Society for Medical Oncology, the leading professional organization for medical oncology, is pleased to announce the TAT (Targeted Anticancer Therapies) International Congress 2019, the premier forum for discussion of early phase drug development and translational research.

Next Gen Immuno-Oncology Congress

March 13-14, 2019 London, U.K. www.mnmconferences.com/2nd-Annual-Next-Gen-Immuno-Oncology-Congress The post Next Gen Immuno-Oncology Congress appeared first on GEN - Genetic Engineering and Biotechnology News.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks